The prevention and treatment of venous thromboembolic disease after total hip arthroplasty is a controversial issue that is important to orthopaedic surgeons and their patients. Important considerations include current risk factors, the efficacy and safety of preventive agents, the optimal duration of treatment with prophylaxis, the value of routine screening, and treatment recommendations after total hip arthroplasty.





Polls results
1

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
100% Article relates to my practice (6/6)
0% Article does not relate to my practice (0/6)
0% Undecided (0/6)
2

Will this article lead to more cost-effective healthcare?

66% Yes (4/6)
16% No (1/6)
16% Undecided (1/6)
3

Was this article biased? (commercial or personal)

0% Yes (0/6)
100% No (6/6)
0% Undecided (0/6)
4

What level of evidence do you think this article is?

0% Level 1 (0/6)
16% Level 2 (1/6)
50% Level 3 (3/6)
0% Level 4 (0/6)
33% Level 5 (2/6)